Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21057929 | 1.00 | LMNA (0.40) | LMNAALDH1A1AKR1C3AKR1C1SMN1; SMN2 | |
| SCHEMBL21057931 | 1.00 | LMNA (0.40) | LMNAALDH1A1AKR1C3AKR1C1SMN1; SMN2 | |
| SCHEMBL21057926 | 1.00 | LMNA (0.40) | LMNAALDH1A1AKR1C3AKR1C1SMN1; SMN2 | |
| SCHEMBL21138531 | 0.85 | TDP1 (0.40) | LMNAALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL21057907 | 0.85 | TDP1 (0.40) | LMNAALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL21104519 | 0.85 | TDP1 (0.40) | LMNAALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL29508338 | 0.85 | TDP1 (0.40) | LMNAALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL24378373 | 0.83 | TP53 (0.48) | LMNAALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL21058142 | 0.83 | TP53 (0.48) | LMNAALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL24282688 | 0.83 | CYP2C19 (0.42) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265078-A1 | SUBSTITUTED PYRROLIDINE AMINES AND AMIDES VI | GRUENENTHAL GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| US-20230265078-A1 | SUBSTITUTED PYRROLIDINE AMINES AND AMIDES VI | GRUENENTHAL GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| EP-3728233-B1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-20 | — | — | EP | disclosed |
| US-20220089573-A1 | SUBSTITUTED PYRROLIDINE AMIDES III | Grünenthal GmbH (DE) | 2022-03-24 | — | — | US | disclosed |
| WO-2022008705-A1 | SUBSTITUTED PYRROLIDINE AMINES AND AMIDES AS MEDIATOR OF THE GLUCOCORTOID RECEPTOR | Grünenthal GmbH (DE) | 2022-01-13 | — | — | WO | disclosed |
| US-20190185455-A1 | Substituted Pyrrolidine Amides I | GRUENENTHAL GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089573-A1 | SUBSTITUTED PYRROLIDINE AMIDES III | NR3C1, NR3C2, MC2R | LMNA 4699/4885ALDH1A1 1199/4885AKR1C3 213/4885 |
| US-20230265078-A1 | SUBSTITUTED PYRROLIDINE AMINES AND AMIDES VI | NR3C1, MC2R, NR3C2 | LMNA 4500/4885ALDH1A1 1331/4885AKR1C3 267/4885 |
| US-20190185455-A1 | Substituted Pyrrolidine Amides I | NR3C1, NR3C2, NR5A1 | LMNA 4685/4885ALDH1A1 814/4885AKR1C3 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.